Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,321

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Metabolism and Disposition Kinetics of Nicotine

Hukkanen, Janne, Jacob, Pleyton, Benowitz, Neal L.·2005·Pharmacological Reviews
DOI 10.1124/pr.57.1.3
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/pr.57.1.3

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 427

  1. Abu-Bakar, 2004, Acute cadmium chloride administration induces hepatic and renal CYP2A5 mRNA, protein and activity in the mouse: involvement of transcription factor NRF2, Toxicol Lett, 148, 199, 10.1016/j.toxlet.2003.10.029 · DOI
  2. Ahijevych, 1997, Nicotine dependence and smoking topography among black and white women, Res Nurs Health, 20, 505, 10.1002/(SICI)1098-240X(199712)20:6<505::AID-NUR5>3.0.CO;2-Q · DOI
  3. Ahijevych, 2002, Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women, Nicotine Tob Res, 4, 423, 10.1080/1462220021000018452 · DOI
  4. Aislaitner, 1992, In vitro studies on (-)-nornicotine, Med Sci Res, 20, 897
  5. Albert, 1999, The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes, Endocrinology, 140, 3292, 10.1210/endo.140.7.6853 · DOI
  6. Anderson, 1995, Characterization of [3H]ABT-418: a novel cholinergic channel ligand, J Pharmacol Exp Ther, 273, 1434, 10.1016/S0022-3565(25)09671-5 · DOI
  7. Andersson, 1997, The influence of cigarette consumption and smoking machine yields of tar and nicotine on the nicotine uptake and oral mucosal lesions in smokers, J Oral Pathol Med, 26, 117, 10.1111/j.1600-0714.1997.tb00033.x · DOI
  8. Ariyoshi, 2002, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers, Cancer Epidemiol Biomarkers Prev, 11, 890
  9. Ariyoshi, 2001, A novel single nucleotide polymorphism altering stability and activity of CYP2A6, Biochem Biophys Res Commun, 281, 810, 10.1006/bbrc.2001.4422 · DOI
  10. Ariyoshi, 2000, Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C, Pharmacogenetics, 10, 687, 10.1097/00008571-200011000-00003 · DOI
  11. Armitage, 1978, Absorption of nicotine from small cigars, Clin Pharmacol Ther, 23, 143, 10.1002/cpt1978232143 · DOI
  12. Armitage, 1975, Absorption and metabolism of nicotine from cigarettes, Br Med J, 4, 313, 10.1136/bmj.4.5992.313 · DOI
  13. Armstrong, 1998, Enantiomeric composition of nicotine in smokeless tobacco, medicinal products and commercial reagents, Chirality, 10, 587, 10.1002/(SICI)1520-636X(1998)10:7<587::AID-CHIR6>3.0.CO;2-# · DOI
  14. Armstrong, 1999, Enantiomeric composition of nornicotine, anatabine and anabasine in tobacco, Chirality, 11, 82, 10.1002/(SICI)1520-636X(1999)11:1<82::AID-CHIR14>3.0.CO;2-C · DOI
  15. Asikainen, 2003, Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes, Toxicol In Vitro, 17, 449, 10.1016/S0887-2333(03)00065-1 · DOI
  16. Ayesh, 1988, Deficient nicotine N-oxidation in two sisters with trimethylaminuria, Br J Clin Pharmacol, 25, 664P
  17. Azuma, 1999, Metabolism and disposition of GTS-21, a novel drug for Alzheimer’s disease, Xenobiotica, 29, 747, 10.1080/004982599238362 · DOI
  18. Bailey, 1991, Interaction of citrus juices with felodipine and nifedipine, Lancet, 337, 268, 10.1016/0140-6736(91)90872-M · DOI
  19. Baker, 2001, Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples, Biochem Pharmacol, 62, 713, 10.1016/S0006-2952(01)00716-X · DOI
  20. Balabanova, 1992, Nicotine excretion by the apocrine and eccrine sweat in smokers and passive smokers, Hautarzt, 43, 73
  21. Balabanova, 1995, Detection of nicotine in eccrine sweat after stimulation of sweat glands during nicotine withdrawal, Hautarzt, 46, 255, 10.1007/s001050050250 · DOI
  22. Balabanova, 1990, Detection of drugs in sweat, Beitr Gerichtl Med, 48, 45
  23. Balfour, 2002, The neurobiology of tobacco dependence: a commentary, Respiration, 69, 7, 10.1159/000049362 · DOI
  24. Bannon, 1998, Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors, Science (Wash DC), 279, 77, 10.1126/science.279.5347.77 · DOI
  25. Baranowski, 1998, Determination of nicotine, cotinine and caffeine in meconium using high-performance liquid chromatography, J Chromatogr B Biomed Sci Appl, 707, 317, 10.1016/S0378-4347(97)00619-1 · DOI
  26. Beckett, 1970, Absorption of (-)-nicotine-l-N-oxide in man and its reduction in the gastrointestinal tract, J Pharm Pharmacol, 22, 722, 10.1111/j.2042-7158.1970.tb12767.x · DOI
  27. Beckett, 1972, A possible relation between pKa 1 and lipid solubility and the amounts excreted in urine of some tobacco alkaloids given to man, J Pharm Pharmacol, 24, 115, 10.1111/j.2042-7158.1972.tb08943.x · DOI
  28. Beckett, 1973, Proceedings: In vitro metabolic N-oxidation of the minor tobacco alkaloids, (-)methylanabasine and (-)anabasine to yield a hydroxylamine and a nitrone in lung and liver homogenates, J Pharm Pharmacol, 25, 171P
  29. Beedham, 2003, Ziprasidone metabolism, aldehyde oxidase and clinical implications, J Clin Psychopharmacol, 23, 229, 10.1097/01.jcp.0000084028.22282.f2 · DOI
  30. Bencherif, 1996, RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization, J Pharmacol Exp Ther, 279, 1413, 10.1016/S0022-3565(25)21302-7 · DOI
  31. Bendayan, 1990, Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans, Eur J Clin Pharmacol, 38, 165, 10.1007/BF00265978 · DOI
  32. Benowitz, 1990, Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence, NIDA Res Monogr, 99, 12
  33. Benowitz, 1995, Clinical pharmacology of transdermal nicotine, Eur J Pharm Biopharm, 41, 168
  34. Benowitz, 1996, Cotinine as a biomarker of environmental tobacco smoke exposure, Epidemiol Rev, 18, 188, 10.1093/oxfordjournals.epirev.a017925 · DOI
  35. Benowitz, 1996, Pharmacology of nicotine: addiction and therapeutics, Annu Rev Pharmacol Toxicol, 36, 597, 10.1146/annurev.pa.36.040196.003121 · DOI · Paper page
  36. Benowitz, 1999, Nicotine addiction, Prim Care, 26, 611, 10.1016/S0095-4543(05)70120-2 · DOI
  37. Benowitz, 2001, Deficient C-oxidation of nicotine continued, Clin Pharmacol Ther, 70, 567
  38. Benowitz, 1983, Smokers of low-yield cigarettes do not consume less nicotine, N Engl J Med, 309, 139, 10.1056/NEJM198307213090303 · DOI
  39. Benowitz, 2004, Mentholated cigarette smoking inhibits nicotine metabolism, J Pharmacol Exp Ther, 310, 1208, 10.1124/jpet.104.066902 · DOI
  40. Benowitz, 1984, Daily intake of nicotine during cigarette smoking, Clin Pharmacol Ther, 35, 499, 10.1038/clpt.1984.67 · DOI
  41. Benowitz, 1985, Nicotine renal excretion rate influences nicotine intake during cigarette smoking, J Pharmacol Exp Ther, 234, 153, 10.1016/S0022-3565(25)23322-5 · DOI
  42. Benowitz, 1994, Metabolism of nicotine to cotinine studied by a dual stable isotope method, Clin Pharmacol Ther, 56, 483, 10.1038/clpt.1994.169 · DOI · Paper page
  43. Benowitz, 2000, Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism, Clin Pharmacol Ther, 67, 653, 10.1067/mcp.2000.107086 · DOI
  44. Benowitz, 2001, Trans-3′-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking, Br J Clin Pharmacol, 51, 53, 10.1046/j.1365-2125.2001.01309.x · DOI · Paper page
  45. Benowitz, 1991, Stable isotope studies of nicotine kinetics and bioavailability, Clin Pharmacol Ther, 49, 270, 10.1038/clpt.1991.28 · DOI
  46. Benowitz, 1994, Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine, J Pharmacol Exp Ther, 268, 296, 10.1016/S0022-3565(25)38479-X · DOI
  47. Benowitz, 1982, Interindividual variability in the metabolism and cardiovascular effects of nicotine in man, J Pharmacol Exp Ther, 221, 368, 10.1016/S0022-3565(25)33068-5 · DOI · Paper page
  48. Benowitz, 1996, CYP2D6 phenotype and the metabolism of nicotine and cotinine, Pharmacogenetics, 6, 239, 10.1097/00008571-199606000-00006 · DOI
  49. Benowitz, 1995, Deficient C-oxidation of nicotine, Clin Pharmacol Ther, 57, 590, 10.1016/0009-9236(95)90044-6 · DOI
  50. Benowitz, 1987, Determinants of nicotine intake while chewing nicotine polacrilex gum, Clin Pharmacol Ther, 41, 467, 10.1038/clpt.1987.58 · DOI
  51. Benowitz, 1982, Circadian blood nicotine concentrations during cigarette smoking, Clin Pharmacol Ther, 32, 758, 10.1038/clpt.1982.233 · DOI
  52. Benowitz, 1983, Cotinine disposition and effects, Clin Pharmacol Ther, 34, 604, 10.1038/clpt.1983.222 · DOI
  53. Benowitz, 1999, Ethnic differences in N-glucuronidation of nicotine and cotinine, J Pharmacol Exp Ther, 291, 1196, 10.1016/S0022-3565(24)35227-9 · DOI
  54. Benowitz, 2002, Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans, J Natl Cancer Inst, 94, 108, 10.1093/jnci/94.2.108 · DOI
  55. Benowitz, 2003, Nicotine metabolite ratio as a predictor of cigarette consumption, Nicotine Tob Res, 5, 621, 10.1080/1462220031000158717 · DOI · Paper page
  56. Benowitz, 2004, Oral contraceptives induce CYP2A6 activity and accelerate nicotine metabolism (abstract), Clin Pharmacol Ther, 75, P36, 10.1016/j.clpt.2003.11.135 · DOI
  57. Benowitz, 2002, CYP2A6 polymorphism and nicotine metabolism (Abstract), Clin Pharmacol Ther, 71, P41
  58. Benwell, 1988, Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain, J Neurochem, 50, 1243, 10.1111/j.1471-4159.1988.tb10600.x · DOI · Paper page
  59. Bergstrom, 1995, Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography, Clin Pharmacol Ther, 57, 309, 10.1016/0009-9236(95)90156-6 · DOI
  60. Berkman, 1995, In vitro-in vivo correlations of human (S)-nicotine metabolism, Biochem Pharmacol, 50, 565, 10.1016/0006-2952(95)00168-Y · DOI
  61. Bieche, 2004, Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma, Breast Cancer Res, 6, R252, 10.1186/bcr784 · DOI
  62. Bolt, 2003, The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine, Int Arch Occup Environ Health, 76, 174, 10.1007/s00420-002-0407-4 · DOI
  63. Borlak, 2003, Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells, Drug Metab Dispos, 31, 888, 10.1124/dmd.31.7.888 · DOI
  64. Bourrie, 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes, J Pharmacol Exp Ther, 277, 321, 10.1016/S0022-3565(25)12826-7 · DOI
  65. Bowman, 1962, Studies on the metabolism of (-)-cotinine in the human, J Pharmacol Exp Ther, 135, 306, 10.1016/S0022-3565(25)26236-X · DOI
  66. Bowman, 1959, Metabolism of nicotine in the human and excretion of pyridine compounds by smokers, J Pharmacol Exp Ther, 127, 92, 10.1016/S0022-3565(25)25663-4 · DOI
  67. Boyland, 1966, Nicotine metabolism, Annu Rep Brit Emp Cancer Campaign, 44, 5
  68. Brandange, 1979, The enzyme “aldehyde oxidase” is an iminium oxidase. Reaction with nicotine delta 1′(5′) iminium ion, Biochem Biophys Res Commun, 91, 991, 10.1016/0006-291X(79)91977-6 · DOI
  69. Brandange, 1979, Synthesis, structure and stability of nicotine Δ1′(5′) iminium ion, an intermediary metabolite of nicotine, Acta Chem Scand B, 33, 187, 10.3891/acta.chem.scand.33b-0187 · DOI
  70. Breese, 1997, Effect of smoking history on [3H]nicotine binding in human postmortem brain, J Pharmacol Exp Ther, 282, 7, 10.1016/S0022-3565(24)36798-9 · DOI · Paper page
  71. Brunnemann, 1974, The pH of tobacco smoke, Fd Cosmet Toxicol, 12, 115, 10.1016/0015-6264(74)90327-7 · DOI
  72. Byrd, 1992, Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine and trans-3′-hydroxycotinine in smokers, Drug Metab Dispos, 20, 192, 10.1016/S0090-9556(25)08565-4 · DOI
  73. Byrd, 1995, Comparison of measured and FTC-predicted nicotine uptake in smokers, Psychopharmacology (Berl), 122, 95, 10.1007/BF02246082 · DOI
  74. Byrd, 1994, Direct determination of cotinine-N-glucuronide in urine using thermospray liquid chromatography/mass spectrometry, Biol Mass Spectrom, 23, 103, 10.1002/bms.1200230210 · DOI
  75. Caldwell, 1992, Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers’ urine, Chem Res Toxicol, 5, 280, 10.1021/tx00026a021 · DOI
  76. Caporaso, 2001, Nicotine metabolism and CYP2D6 phenotype in smokers, Cancer Epidemiol Biomarkers Prev, 10, 261
  77. Caraballo, 1998, Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988–1991, JAMA (J Am Med Assoc), 280, 135, 10.1001/jama.280.2.135 · DOI
  78. Carmella, 1997, Evidence for endogenous formation of tobacco-specific nitrosamines in rats treated with tobacco alkaloids and sodium nitrite, Carcinogenesis, 18, 587, 10.1093/carcin/18.3.587 · DOI
  79. Carmella, 2000, Enantiomeric composition of N′-nitrosonornicotine and N′-nitrosoanatabine in tobacco, Carcinogenesis, 21, 839, 10.1093/carcin/21.4.839 · DOI
  80. Cascorbi, 2003, Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication, Eur J Clin Investig, 33, 17, 10.1046/j.1365-2362.33.s2.3.x · DOI
  81. Cashman, 1992, Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide, Chem Res Toxicol, 5, 639, 10.1021/tx00029a008 · DOI
  82. Cashman, 2002, Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation, Drug Metab Dispos, 30, 1043, 10.1124/dmd.30.10.1043 · DOI
  83. Castorena, 1987, A fatal poisoning from Nicotiana glauca, J Toxicol Clin Toxicol, 25, 429, 10.3109/15563658708992646 · DOI
  84. 1993, Smoking cessation during previous year among adults–United States, 1990 and 1991, MMWR Morb Mortal Wkly Rep, 42, 504
  85. Chauret, 1997, In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat and horse, Drug Metab Dispos, 25, 1130
  86. Chen, 2003, Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter, Mol Pharmacol, 64, 316, 10.1124/mol.64.2.316 · DOI
  87. Chen, 2003, Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa, Biochem Pharmacol, 66, 1245, 10.1016/S0006-2952(03)00476-3 · DOI
  88. Choi, 2003, Pharmacokinetics of a nicotine polacrilex lozenge, Nicotine Tob Res, 5, 635, 10.1080/1462220031000158690 · DOI
  89. Cholerton, 1988, The pre-eminence of nicotine N-oxidation and its diminution after carbamizole administration, Br J Clin Pharmacol, 26, 652P
  90. Christian, 2004, Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene, Mol Pharmacol, 65, 1405, 10.1124/mol.65.6.1405 · DOI
  91. Clark, 1965, Comparison of pharmacological activity of nicotine and related alkaloids occurring in cigarette smoke, Arch Int Pharmacodyn Ther, 156, 363
  92. Collier, 1994, Cotinine elimination and its use as a biomarker in young children involuntarily exposed to environmental tobacco smoke, Indoor Environ, 3, 353
  93. Compton, 1997, A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration, Aliment Pharmacol Ther, 11, 865, 10.1046/j.1365-2036.1997.00236.x · DOI
  94. Cosford, 1996, (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors, J Med Chem, 39, 3235, 10.1021/jm960328w · DOI
  95. Court, 1998, Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use, Neuroscience, 87, 63, 10.1016/S0306-4522(98)00088-8 · DOI · Paper page
  96. Crawford, 1998, Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells, Carcinogenesis, 19, 1867, 10.1093/carcin/19.10.1867 · DOI
  97. Crooks, 1988, N-Methylation of nicotine enantiomers by human liver cytosol, J Pharm Pharmacol, 40, 153, 10.1111/j.2042-7158.1988.tb05207.x · DOI
  98. Dahlstrom, 1990, Nicotine and cotinine concentrations in the nursing mother and her infant, Acta Paediatr Scand, 79, 142, 10.1111/j.1651-2227.1990.tb11430.x · DOI
  99. Daigo, 2002, A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur, Pharmacogenetics, 12, 299, 10.1097/00008571-200206000-00005 · DOI
  100. Dajani, 1975, Reduction in vivo of (minus)-nicotine-1′-N-oxide by germ-free and conventional rats, Biochem Pharmacol, 24, 648, 10.1016/0006-2952(75)90189-6 · DOI
  101. Dalet-Beluche, 1992, Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross reactivity with human forms, Eur J Biochem, 204, 641, 10.1111/j.1432-1033.1992.tb16677.x · DOI
  102. Davila-Garcia, 1997, [125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors, J Pharmacol Exp Ther, 282, 445, 10.1016/S0022-3565(24)36785-0 · DOI
  103. Degawa, 1994, Metabolic activation and carcinogen-DNA adduct detection in human larynx, Cancer Res, 54, 4915
  104. de Leon, 2002, Total cotinine in plasma: a stable biomarker for exposure to tobacco smoke, J Clin Psychopharmacol, 22, 496, 10.1097/00004714-200210000-00009 · DOI
  105. Dempsey, 2002, Accelerated metabolism of nicotine and cotinine in pregnant smokers, J Pharmacol Exp Ther, 301, 594, 10.1124/jpet.301.2.594 · DOI · Paper page
  106. Dempsey, 1999, The detection of cotinine in hydrolyzed meconium samples, Forensic Sci Int, 102, 167, 10.1016/S0379-0738(99)00052-3 · DOI
  107. Dempsey, 2004, Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity, Clin Pharmacol Ther, 76, 64, 10.1016/j.clpt.2004.02.011 · DOI
  108. Denton, 2004, Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6, Biochem Pharmacol, 67, 751, 10.1016/j.bcp.2003.10.022 · DOI
  109. Derauf, 2003, Agreement between maternal self-reported ethanol intake and tobacco use during pregnancy and meconium assays for fatty acid ethyl esters and cotinine, Am J Epidemiol, 158, 705, 10.1093/aje/kwg215 · DOI
  110. De Schepper, 1987, Kinetics of cotinine after oral and intravenous administration to man, Eur J Clin Pharmacol, 31, 583, 10.1007/BF00606635 · DOI
  111. Domino, 1993, The nicotine content of common vegetables, N Engl J Med, 329, 437, 10.1056/NEJM199308053290619 · DOI
  112. Domino, 2003, Comparative American and Japanese tobacco smoke uptake parameters after overnight tobacco deprivation, Prog Neuropsychopharmacol Biol Psychiatry, 27, 973, 10.1016/S0278-5846(03)00157-X · DOI
  113. Donato, 2000, CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers, Drug Metab Dispos, 28, 1321, 10.1016/S0090-9556(24)15080-5 · DOI
  114. Dresser, 2000, Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition, Clin Pharmacokinet, 38, 41, 10.2165/00003088-200038010-00003 · DOI · Paper page
  115. Dwoskin, 1992, Inhibition of [3H]dopamine uptake into rat striatal slices by quaternary N-methylated nicotine metabolites, Life Sci, 50, PL233, 10.1016/0024-3205(92)90533-U · DOI
  116. Edwards, 2003, Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices, Drug Metab Dispos, 31, 282, 10.1124/dmd.31.3.282 · DOI
  117. Eldirdiri, 1997, The in vitro metabolism of norcotinine and related biotransformation products by microsomal preparations, Eur J Drug Metab Pharmacokinet, 22, 385, 10.1007/BF03190974 · DOI
  118. English, 1994, Black-white differences in serum cotinine levels among pregnant women and subsequent effects on infant birth weight, Am J Public Health, 84, 1439, 10.2105/AJPH.84.9.1439 · DOI
  119. Etzel, 1985, Urine cotinine excretion in neonates exposed to tobacco smoke products in utero, J Pediatr, 107, 146, 10.1016/S0022-3476(85)80637-5 · DOI
  120. Fant, 2000, A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches, Pharmacol Biochem Behav, 67, 479, 10.1016/S0091-3057(00)00399-3 · DOI
  121. Flammang, 1992, Nicotine metabolism by cDNA-expressed human cytochrome P-450s, Biochem Arch, 8, 1
  122. Fowler, 1954, Redetermination of ionization constants of nicotine, J Appl Chem, 4, 449, 10.1002/jctb.5010040811 · DOI
  123. Fujita, 2001, Screening of organosulfur compounds as inhibitors of human CYP2A6, Drug Metab Dispos, 29, 983
  124. Fukada, 2002, Transport mechanisms of nicotine across the human intestinal epithelial cell line Caco-2, J Pharmacol Exp Ther, 302, 532, 10.1124/jpet.102.034629 · DOI
  125. Fukami, 2004, A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo, Clin Pharmacol Ther, 76, 519, 10.1016/j.clpt.2004.08.014 · DOI
  126. Gerbal-Chaloin, 2002, Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor, J Biol Chem, 277, 209, 10.1074/jbc.M107228200 · DOI
  127. Gerbal-Chaloin, 2001, Induction of CYP2C genes in human hepatocytes in primary culture, Drug Metab Dispos, 29, 242
  128. Gervot, 1999, Human CYP2B6: expression, inducibility and catalytic activities, Pharmacogenetics, 9, 295, 10.1097/00008571-199906000-00004 · DOI
  129. Getchell, 1993, Immunohistochemical localization of a cytochrome P-450 isozyme in human nasal mucosa: age-related trends, Ann Otol Rhinol Laryngol, 102, 368, 10.1177/000348949310200509 · DOI
  130. Ghosheh, 2002, Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue and interspecies hepatic variation, Drug Metab Dispos, 30, 1478, 10.1124/dmd.30.12.1478 · DOI
  131. Ghosheh, 2002, N-Glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases, Drug Metab Dispos, 30, 991, 10.1124/dmd.30.9.991 · DOI
  132. Gilmore, 2001, Identification of a 43-kDa protein in human liver cytosol that binds to the 3′-untranslated region of CYP2A6 mRNA, Biochem Pharmacol, 62, 669, 10.1016/S0006-2952(01)00720-1 · DOI
  133. Giovino, 2004, Epidemiology of menthol cigarette use, Nicotine Tob Res, 6, S67, 10.1080/14622203710001649696 · DOI
  134. Godoy, 2002, CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism, Carcinogenesis, 23, 611, 10.1093/carcin/23.4.611 · DOI
  135. Gori, 1986, Mouth versus deep airways absorption of nicotine in cigarette smokers, Pharmacol Biochem Behav, 25, 1181, 10.1016/0091-3057(86)90108-5 · DOI
  136. Gori, 1985, Analytical cigarette yields as predictors of smoke bioavailability, Regul Toxicol Pharmacol, 5, 314, 10.1016/0273-2300(85)90045-5 · DOI
  137. Gorrod, 1994, The metabolism of alicyclic amines to reactive iminium ion intermediates, Eur J Drug Metab Pharmacokinet, 19, 209, 10.1007/BF03188923 · DOI
  138. Gorrod, 1982, The metabolism of nicotine-delta 1′(5′)-iminium ion, in vivo and in vitro, Eur J Drug Metab Pharmacokinet, 7, 293, 10.1007/BF03189632 · DOI
  139. Gorrod, 1975, The metabolism of tobacco alkaloids, 35, 10.1016/B978-0-12-107606-1.50008-2 · DOI
  140. Gourlay, 1996, The benefits of stopping smoking and the role of nicotine replacement therapy in older patients, Drugs Aging, 9, 8, 10.2165/00002512-199609010-00002 · DOI
  141. Gourlay, 1997, Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray and intravenous nicotine, Clin Pharmacol Ther, 62, 453, 10.1016/S0009-9236(97)90124-7 · DOI
  142. Gow, 2001, Neonatal hepatic drug elimination, Pharmacol Toxicol, 88, 3, 10.1034/j.1600-0773.2001.088001003.x · DOI
  143. Gries, 1996, Chronopharmacokinetics of nicotine, Clin Pharmacol Ther, 60, 385, 10.1016/S0009-9236(96)90195-2 · DOI
  144. Grusz-Harday, 1967, Fatal nicotine poisoning, Arch Toxikol, 23, 35, 10.1007/BF00577697 · DOI
  145. Guthrie, 1999, Arterial/venous plasma nicotine concentrations following nicotine nasal spray, Eur J Clin Pharmacol, 55, 639, 10.1007/s002280050686 · DOI
  146. Hadidi, 1997, A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin, Food Chem Toxicol, 35, 903, 10.1016/S0278-6915(97)00066-5 · DOI
  147. Hammond, 1991, Metabolism of nicotine by rat liver cytochromes P-450. Assessment utilizing monoclonal antibodies to nicotine and cotinine, Drug Metab Dispos, 19, 804, 10.1016/S0090-9556(25)08898-1 · DOI
  148. Harke, 1974, Demethylation of nicotine and cotinine in pigs, Res Commun Chem Pathol Pharmacol, 9, 595
  149. Hatsukami, 1998, Effects of cotinine on cigarette self-administration, Psychopharmacology (Berl), 138, 184, 10.1007/s002130050661 · DOI
  150. Hatsukami, 1998, Cotinine: effects with and without nicotine, Psychopharmacology (Berl), 135, 141, 10.1007/s002130050495 · DOI
  151. Hatsukami, 1997, Safety of cotinine in humans: physiologic, subjective and cognitive effects, Pharmacol Biochem Behav, 57, 643, 10.1016/S0091-3057(97)80001-9 · DOI
  152. Hecht, 1998, Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines, Chem Res Toxicol, 11, 559, 10.1021/tx980005y · DOI
  153. Hecht, 2003, Tobacco carcinogens, their biomarkers and tobacco-induced cancer, Nat Rev Cancer, 3, 733, 10.1038/nrc1190 · DOI
  154. Hecht, 1999, Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation, Cancer Res, 59, 590
  155. Hecht, 1999, Effects of watercress consumption on urinary metabolites of nicotine in smokers, Cancer Epidemiol Biomarkers Prev, 8, 907
  156. Hecht, 1999, Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl)butanoic acid in human urine: a substantial pathway of nicotine metabolism, Chem Res Toxicol, 12, 172, 10.1021/tx980214i · DOI
  157. Hecht, 2000, 2′-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor, Proc Natl Acad Sci USA, 97, 12493, 10.1073/pnas.220207697 · DOI
  158. Hecht, 1989, The relevance of tobacco-specific nitrosamines to human cancer, Cancer Surv, 8, 273
  159. Hellmold, 1998, Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties, J Clin Endocrinol Metab, 83, 886
  160. Henningfield, 1993, Nicotine delivery kinetics and abuse liability, J Consult Clin Psychol, 61, 743, 10.1037/0022-006X.61.5.743 · DOI · Paper page
  161. Henningfield, 1993, Higher levels of nicotine in arterial than in venous blood after cigarette smoking, Drug Alcohol Depend, 33, 23, 10.1016/0376-8716(93)90030-T · DOI
  162. Herzig, 1998, Effects of cotinine on information processing in nonsmokers, Psychopharmacology (Berl), 135, 127, 10.1007/s002130050493 · DOI
  163. Hesse, 2004, Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes, Pharmacogenetics, 14, 225, 10.1097/00008571-200404000-00002 · DOI
  164. Hibberd, 1981, Nicotine delta 1 ″(5)′ iminium ion: a reactive intermediate in nicotine metabolism, Adv Exp Med Biol, 136, 1121
  165. Holladay, 1997, Neuronal nicotinic acetylcholine receptors as targets for drug discovery, J Med Chem, 40, 4169, 10.1021/jm970377o · DOI
  166. Howard, 2003, CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence, Pharmacogenetics, 13, 321, 10.1097/00008571-200306000-00003 · DOI
  167. Howard, 2003, Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics, Br J Pharmacol, 138, 1376, 10.1038/sj.bjp.0705146 · DOI
  168. Hukkanen J, Gourlay SG, Kenkare S, and Benowitz NL (2005) Influence of menstrual cycle on CYP2A6 activity and cardiovascular effects of nicotine. Clin Pharmacol Ther, in press. · DOI · Paper page
  169. Hukkanen, 2002, Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung, Crit Rev Toxicol, 32, 391, 10.1080/20024091064273 · DOI
  170. Hukkanen, 2003, Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells, J Pharmacol Exp Ther, 304, 745, 10.1124/jpet.102.038208 · DOI
  171. Hurt, 1994, Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement, JAMA (J Am Med Assoc), 271, 595, 10.1001/jama.1994.03510320035026 · DOI
  172. Iscan, 1994, Interindividual variability of coumarin 7-hydroxylation in a Turkish population, Eur J Clin Pharmacol, 47, 315, 10.1007/BF00191161 · DOI
  173. Iwase, 1991, Respiratory nicotine absorption in non-smoking females during passive smoking, Int Arch Occup Environ Health, 63, 139, 10.1007/BF00379078 · DOI
  174. Jacob, 1990, Synthesis of (3′R,5′S)-trans-3′-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3′-hydroxycotinine in humans is highly stereoselective, J Med Chem, 33, 1888, 10.1021/jm00169a009 · DOI
  175. Jacob, 1997, Metabolism of (-)-(S)-nicotine by guinea pig and rat brain: identification of cotinine, Eur J Drug Metab Pharmacokinet, 22, 391, 10.1007/BF03190975 · DOI
  176. Jacob, 1999, Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars and pipes, Am J Public Health, 89, 731, 10.2105/AJPH.89.5.731 · DOI
  177. Jain, 2004, Modulators of nicotinic acetylcholine receptors as analgesics, Curr Opin Investig Drugs, 5, 76
  178. Jani, 2002, Medical therapy for ulcerative colitis, Gastroenterol Clin North Am, 31, 147, 10.1016/S0889-8553(01)00010-3 · DOI
  179. Janmohamed, 2001, Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450, Biochem Pharmacol, 62, 777, 10.1016/S0006-2952(01)00718-3 · DOI
  180. Jarvis, 2001, Nicotine yield from machine-smoked cigarettes and nicotine intakes in smokers: evidence from a representative population survey, J Natl Cancer Inst, 93, 134, 10.1093/jnci/93.2.134 · DOI
  181. Jenner, 1973, Comparative in vitro hepatic metabolism of some tertiary N-methyl tobacco alkaloids in various species, Res Commun Chem Pathol Pharmacol, 6, 829
  182. Jenner, 1973, Species variation in the metabolism of R-(+)- and S-(-)-nicotine by alpha-C- and N-oxidation in vitro, Xenobiotica, 3, 573, 10.3109/00498257309151545 · DOI
  183. Johansson, 1991, Absolute bioavailability of nicotine applied to different nasal regions, Eur J Clin Pharmacol, 41, 585, 10.1007/BF00314989 · DOI
  184. Kawamoto, 2000, Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene, Mol Endocrinol, 14, 1897, 10.1210/mend.14.11.0547 · DOI · Paper page
  185. Keenan, 1994, Pharmacodynamic effects of cotinine in abstinent cigarette smokers, Clin Pharmacol Ther, 55, 581, 10.1038/clpt.1994.72 · DOI
  186. Kemp, 1997, Postmortem distribution of nicotine and cotinine from a case involving the simultaneous administration of multiple nicotine transdermal systems, J Anal Toxicol, 21, 310, 10.1093/jat/21.4.310 · DOI
  187. Khan, 2001, A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception, J Pharmacol Exp Ther, 297, 230, 10.1016/S0022-3565(24)29532-X · DOI
  188. Kharasch, 2000, Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity, Drug Metab Dispos, 28, 28, 10.1016/S0090-9556(24)14998-7 · DOI
  189. Kirby, 1996, Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis, Toxicol Pathol, 24, 458, 10.1177/019262339602400408 · DOI
  190. Kitagawa, 2003, Safety, pharmacokinetics and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers, Neuropsychopharmacology, 28, 542, 10.1038/sj.npp.1300028 · DOI
  191. Kitagawa, 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP, Biochem Biophys Res Commun, 262, 146, 10.1006/bbrc.1999.1182 · DOI
  192. Kitagawa, 2001, CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity, J Biol Chem, 276, 17830, 10.1074/jbc.M009432200 · DOI
  193. Kiyotani, 2002, Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians, Drug Metab Pharmacokin, 17, 482, 10.2133/dmpk.17.482 · DOI
  194. Kiyotani, 2003, Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9), Pharmacogenetics, 13, 689, 10.1097/00008571-200311000-00005 · DOI
  195. Klus, 1977, A study of the optical activity of smoke nicotines, Fachliche Mitt Oesterr Tabakregie, 17, 331
  196. Koenigs, 1997, Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen, Drug Metab Dispos, 25, 1407
  197. Koskela, 1999, Expression of CYP2A genes in human liver and extrahepatic tissues, Biochem Pharmacol, 57, 1407, 10.1016/S0006-2952(99)00015-5 · DOI
  198. Kozlowski, 1998, Filter ventilation and nicotine content of tobacco in cigarettes from Canada, the United Kingdom and the United States, Tob Control, 7, 369, 10.1136/tc.7.4.369 · DOI
  199. Kratz, 1976, Coumarin-7-hydroxylase activity in microsomes from needle biopsies of normal and diseased human liver, Eur J Clin Pharmacol, 10, 133, 10.1007/BF00609472 · DOI
  200. Krause, 2003, Human kidney flavin-containing monooxygenases and their potential roles in cysteine s-conjugate metabolism and nephrotoxicity, J Pharmacol Exp Ther, 304, 185, 10.1124/jpet.102.042911 · DOI

200 of 427 shown

Cited by

See all 1,321

Metadata

Authors
Hukkanen, J., Jacob, P., & Benowitz, N. L.
Venue
Pharmacological Reviews
Publisher
Elsevier BV
Published
2005-03
Volume
57
Issue
1
Pages
79-115
ISSN
0031-6997
DOI
10.1124/pr.57.1.3
Cited by
1,321
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolism and Disposition Kinetics of Nicotine. https://app.cochat.ai/papers/10.1124/pr.57.1.3
The paper
Hukkanen, J., Jacob, P., & Benowitz, N. L. (2005). Metabolism and Disposition Kinetics of Nicotine. Pharmacological Reviews. https://doi.org/10.1124/pr.57.1.3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.